Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

December 11, 2023

https://www.globenewswire.com/news-release/2023/12/11/2793907/0/en/Capricor-Therapeutics-Announces-Continuation-of-Phase-3-HOPE-3-Trial-of-CAP-1002-in-Duchenne-Muscular-Dystrophy-Based-on-Completion-of-Interim-Futility-Analysis.html

–Favorable Interim Futility Analysis Results–

–Successful Completion Triggers First Milestone Payment Under U.S. Agreement with Nippon Shinyaku–

Read more at globenewswire.com

Related news for (CAPR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.